CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Cellular immunotherapy for medulloblastoma.
Cellular immunotherapy for medulloblastoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
髓母细胞瘤(MB)是儿童中最常见的恶性脑肿瘤,约占所有儿童原发性脑肿瘤的20%。目前的治疗包括最大程度的手术切除以及积极的放疗和化疗。三分之一的接受治疗的患者无法治愈,而幸存者往往留下毁灭性的长期副作用。这一患者群体迫切需要新的高效靶向治疗。细胞免疫治疗旨在增强和利用免疫细胞靶向肿瘤,并已在多种癌症中被证明是成功的。然而,对于MB,细胞免疫治疗的知识和可能性仍然有限。在这篇综述中,我们全面概述了MB细胞免疫治疗的现状,从基础体外研究到体内模型以及(正在进行的)临床试验。此外,我们将我们的发现与胶质瘤——一种类似MB的颅内肿瘤——的细胞免疫治疗进行了比较。最后,讨论了MB未来的可能性,以提高疗效和安全性。
Medulloblastoma (MB) is the most common malignant brain tumor in children, making up ~20% of all primary pediatric brain tumors. Current therapies consist of maximal surgical resection and aggressive radio- and chemotherapy.
A third of the treated patients cannot be cured and survivors are often left with devastating long-term side effects. Novel efficient and targeted treatment is desperately needed for this patient population. Cellular immunotherapy aims to enhance and utilize immune cells to target tumors, and has been proven successful in various cancers.
However, for MB, the knowledge and possibilities of cellular immunotherapy are limited. In this review, we provide a comprehensive overview of the current status of cellular immunotherapy for MB, from fundamental in vitro research to in vivo models and (ongoing) clinical trials.
In addition, we compare our findings to cellular immunotherapy in glioma, an MB-like intracranial tumor.
Finally, future possibilities for MB are discussed to improve efficacy and safety.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。